ACCU-CHEK Connect Personal Diabetes Management Study (PDM CONNECT)

ACCU-CHEK Connect Personal Diabetes Management Study (PDM)

This post-market, interventional, prospective, single arm, the United States (US) based multi-center study will assess the change in treatment satisfaction of participants who utilize the ACCU-CHEK Connect Diabetes Management System over a period of 6 months.

Study Overview

• Status: Completed
• Conditions: Diabetes Mellitus, Type 1
• Intervention / Treatment: Device: ACCU-CHEK

• Study Type: Interventional
• Enrollment (Actual): 122
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Alabama
    • Montgomery, Alabama, United States, 36105
  • California
    • Huntington Beach, California, United States, 92648
  • Georgia
    • Atlanta, Georgia, United States, 30318
    • Macon, Georgia, United States, 31210
  • Mississippi
    • Ocean Springs, Mississippi, United States, 39564
  • Nebraska
    • Lincoln, Nebraska, United States, 68521
  • North Carolina
    • Raleigh, North Carolina, United States, 27609
    • Wilmington, North Carolina, United States, 28401
  • Pennsylvania
    • Pottstown, Pennsylvania, United States, 19464
  • Tennessee
    • Bristol, Tennessee, United States, 37620
  • Texas
    • Plano, Texas, United States, 75075

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Diagnosis of type 1 or type 2 diabetes for greater than or equal to (>=) 6 months
• Currently using insulin as a component of the diabetes therapy
• Allow and be able to provide self-monitoring of blood glucose (SMBG) data at least 1 month prior to study start
• SMBG frequency as confirmed by site SMBG data download of participants meter(s): Basal insulin treated participants - SMBG >=5 times per week and Multiple dose insulin participants - SMBG >=2 times per day
• Glycosylated hemoglobin (HbA1c) of >=7.5 percentage (per local laboratory obtained less than or equal to [<= 3] months of Baseline)
• Able to read and write in English language
• Currently using a Smartphone and have experience with downloading at minimum one application
• Smartphone compatibility; must be able to download the ACCU-CHEK Connect system application accordingly
• Naive to the ACCU-CHEK Connect system
• Willing to comply with study procedures

Exclusion Criteria:

• Treatment with insulin pump therapy
• Any use of continuous glucose monitoring (CGM) to manage their diabetes during the course of the study
• Visually impaired
• Women who are pregnant, lactating or planning to become pregnant during the study period
• Diagnosed with any clinically significant condition (for example anemia, major organ system disease, infections, psychosis or cognitive impairment)
• Participant requires chronic steroid in adrenal suppressive doses, other immuno-modulatory medication or chemotherapy
• Participant is the investigator or any sub-investigator, general practitioner, practice staff, pharmacist, research assistant or other staff or relative of those directly involved in the conduct of the study and design of the protocol

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: ACCU-CHEK; All participants will utilize ACCU-CHEK Connect Diabetes Management System containing three primary components: ACCU-CHEK Aviva Connect Blood Glucose Monitoring System intended to be used for the quantitative measurement of glucose, ACCU-CHEK Connect Diabetes Management App indicated as an aid in the treatment of diabetes, and ACCU-CHEK Connect Online Diabetes Management System indicated for use by persons with diabetes or by healthcare professionals in the home or in healthcare facilities.

Device: ACCU-CHEK; ACCU-CHEK Connect Diabetes Management System contains ACCU-CHEK Aviva Connect Blood Glucose Monitoring System, ACCU-CHEK Connect Diabetes Management App, and ACCU-CHEK Connect Online Diabetes Management System.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Treatment Satisfaction: Diabetes Treatment Satisfaction Questionnaire (DTSQc) Score at Week 24	The Diabetes Treatment Satisfaction Questionnaire for change from Baseline (DTSQc) to study end contains 6 items which can be rated from -3='much worse now' to 3='much better now'). The total score is the sum of the scores of the 6 items and ranges from -18 to 18. A higher score indicates more satisfaction. This questionnaire was administered at the end of the study (Week 24) only.	Week 24

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline to Week 24 in Diabetes Distress Scale (DDS) Score	Participants rated their level of diabetes distress by answering 17 questions in in the following areas: Regimen-related Distress, Emotional Burden, Diabetes-related Interpersonal Distress and Physician-related Distress (PD) on a 6-point scale: 1=Not a problem to 6=A very serious problem. The Average Total score ranged from 1 (best) to 6 (worst). Results were calculated using a Linear Mixed Model with study group, visit, group-by-visit interaction, baseline DDS, gender, age, and race as fixed effects; and site and subject as random effects. A negative change from Baseline indicated improvement.	Baseline, Week 24
Mean Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Weeks 12 and 24	Assessment of HbA1c is an indicator of long-term control of diabetes.	Baseline, Weeks 12 and 24
Mean Change From Baseline to Week 24 in Percentage of Glucose Readings in Target Range	Glucose target range was specified as 70-180 milligrams per deciliter (mg/dL).	Baseline, Week 24
Change From Baseline to Week 24 in Mean Blood Glucose Level	Blood glucose is a type of sugar in blood and is measured to assess a participant's control of diabetes.	Baseline, Week 24
Change From Baseline to Week 24 in Glycemic Variability	Glycemic variability refers to swings in blood glucose levels. Mean glycemic variability is expressed as a standard deviation of blood glucose data. A negative number indicates a decrease in glucose variability. A positive number indicates and increase in glucose variability.	Baseline, Week 24
Incidence of Hypoglycemia	A hypoglycemic reading was defined as a glucose value that fell below the 70 mg/dL level. The incidence of hypoglycemia was defined as the number of hypoglycemic readings in the interval divided by the total number of blood glucose checks in the interval.	Baseline, Weeks 12 and 24
Number of Participants With Competency in Self-monitoring of Blood Glucose (SMBG) at Week 24	Competency was defined as appropriate response to high and low glucose values.	Week 24
Percent of Follow-Up Visits With Sufficient SMBG Data	Sufficient SMBG data is based on the ability of the healthcare provider to make informed decisions regarding therapy adjustments.	Up to Week 24
Change From Baseline in the Number of Blood Glucose Checks at Weeks 12 and 24	An increase in the number of blood glucose checks indicates more glycemic control.	Baseline, Weeks 12 and 24
Change From Baseline in Mean Daily Self-Monitoring of Blood Glucose (SMBG) Frequency at Weeks 12 and 24	An increase in SMBG frequency indicates more glycemic control. The average number of daily SMBG measurements per interval was calculated based on the total number of blood glucose readings recorded during the study visit interval.	Baseline, Weeks 12 and 24
Percentage of Blood Glucose Tagged Data	Tagged data specifies the timing of blood glucose recording and includes: fasting, before breakfast, after breakfast, before lunch, after lunch, before dinner, after dinner, and bedtime. The percentage of blood glucose tagged data per interval was calculated as the total number of tagged blood glucose readings during the interval divided by the total number of readings within the interval.	Weeks 12 and 24

Collaborators and Investigators

• Sponsor: Hoffmann-La Roche
• Collaborators: Roche Diabetes Care GmbH
• Investigators: Study Director: Lena Borsa, Hoffmann-La Roche

Publications and helpful links

General Publications

• Mora P, Buskirk A, Lyden M, Parkin CG, Borsa L, Petersen B. Use of a Novel, Remotely Connected Diabetes Management System Is Associated with Increased Treatment Satisfaction, Reduced Diabetes Distress, and Improved Glycemic Control in Individuals with Insulin-Treated Diabetes: First Results from the Personal Diabetes Management Study. Diabetes Technol Ther. 2017 Dec;19(12):715-722. doi: 10.1089/dia.2017.0206. Epub 2017 Oct 13.

Study record dates

Study Major Dates

• Study Start (Actual): December 30, 2015
• Primary Completion (Actual): September 29, 2016
• Study Completion (Actual): February 20, 2017

Study Registration Dates

• First Submitted: November 6, 2015
• First Submitted That Met QC Criteria: November 6, 2015
• First Posted (Estimate): November 9, 2015

Study Record Updates

• Last Update Posted (Actual): November 6, 2017
• Last Update Submitted That Met QC Criteria: October 6, 2017
• Last Verified: October 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Immune System Diseases; Autoimmune Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 1
• Other Study ID Numbers: RD002206

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: Yes